JP2024500870A - 二官能性線状融合コラーゲン局在化免疫調節分子およびその方法 - Google Patents

二官能性線状融合コラーゲン局在化免疫調節分子およびその方法 Download PDF

Info

Publication number
JP2024500870A
JP2024500870A JP2023537915A JP2023537915A JP2024500870A JP 2024500870 A JP2024500870 A JP 2024500870A JP 2023537915 A JP2023537915 A JP 2023537915A JP 2023537915 A JP2023537915 A JP 2023537915A JP 2024500870 A JP2024500870 A JP 2024500870A
Authority
JP
Japan
Prior art keywords
fusion protein
terminus
immunomodulatory fusion
binding domain
operably linked
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023537915A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024500870A5 (https=
Inventor
ナヴィーン メータ，
マイケルソン ジェニファー，
パトリック バウアリー，
ボチョン リー，
ケー． デイン ウィトラップ，
Original Assignee
カリナン アンバー コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カリナン アンバー コーポレイション filed Critical カリナン アンバー コーポレイション
Publication of JP2024500870A publication Critical patent/JP2024500870A/ja
Publication of JP2024500870A5 publication Critical patent/JP2024500870A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023537915A 2020-12-18 2021-12-17 二官能性線状融合コラーゲン局在化免疫調節分子およびその方法 Pending JP2024500870A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063127995P 2020-12-18 2020-12-18
US63/127,995 2020-12-18
PCT/US2021/064224 WO2022133326A1 (en) 2020-12-18 2021-12-17 Bi-functional linear fusion collagen-localized immunomodulatory molecules and methods thereof

Publications (2)

Publication Number Publication Date
JP2024500870A true JP2024500870A (ja) 2024-01-10
JP2024500870A5 JP2024500870A5 (https=) 2024-10-10

Family

ID=82058332

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023537915A Pending JP2024500870A (ja) 2020-12-18 2021-12-17 二官能性線状融合コラーゲン局在化免疫調節分子およびその方法

Country Status (11)

Country Link
US (1) US20240101630A1 (https=)
EP (1) EP4262840A4 (https=)
JP (1) JP2024500870A (https=)
KR (1) KR20230124633A (https=)
CN (1) CN116887850A (https=)
AU (1) AU2021400761A1 (https=)
CA (1) CA3202397A1 (https=)
IL (1) IL303712A (https=)
MX (1) MX2023007326A (https=)
WO (1) WO2022133326A1 (https=)
ZA (1) ZA202306571B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019346335B2 (en) 2018-09-28 2024-07-25 Massachusetts Institute Of Technology Collagen-localized immunomodulatory molecules and methods thereof
WO2025049528A1 (en) * 2023-08-29 2025-03-06 Cullinan Amber Corp. Combination therapies for cancer
WO2025245169A1 (en) * 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload
WO2025255560A1 (en) * 2024-06-07 2025-12-11 Rush University Medical Center Intranasal p40 monomer and anti-p40 homodimer mab for type 1 diabetes

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018027039A1 (en) * 2016-08-03 2018-02-08 Nextcure, Inc. Compositions and methods for modulating lair signal transduction
WO2018151868A2 (en) * 2017-02-16 2018-08-23 Sonnet Bio Therapeutics Albumin binding domain fusion proteins
WO2019173289A1 (en) * 2018-03-05 2019-09-12 The University Of Chicago Methods and compositions for treating cancer with ecm-affinity peptides linked to cytokines
US20190328644A1 (en) * 2018-04-27 2019-10-31 Krystal Biotech, Inc. Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications
WO2020051374A1 (en) * 2018-09-05 2020-03-12 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
WO2020092448A1 (en) * 2018-10-29 2020-05-07 Spin Therapeutics, Llc Compositions and methods for alpha-1-antitrypsin disorders
WO2020163264A1 (en) * 2019-02-04 2020-08-13 Neutrolis, Inc. Engineered human extracellular dnase enzymes for drug candidate selection
WO2020186111A2 (en) * 2019-03-12 2020-09-17 xCella Biosciences, Inc. Vista-binding antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007073661A1 (fr) * 2005-12-26 2007-07-05 Yantai Zhenghai Bio-Technology Co., Ltd. Matieres de squelette de collagene activees et leurs facteurs speciaux de restauration active fusionnee
CA2957717C (en) * 2014-08-12 2021-10-19 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
AU2019271148B9 (en) * 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018027039A1 (en) * 2016-08-03 2018-02-08 Nextcure, Inc. Compositions and methods for modulating lair signal transduction
WO2018151868A2 (en) * 2017-02-16 2018-08-23 Sonnet Bio Therapeutics Albumin binding domain fusion proteins
WO2019173289A1 (en) * 2018-03-05 2019-09-12 The University Of Chicago Methods and compositions for treating cancer with ecm-affinity peptides linked to cytokines
US20190328644A1 (en) * 2018-04-27 2019-10-31 Krystal Biotech, Inc. Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications
WO2020051374A1 (en) * 2018-09-05 2020-03-12 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
WO2020092448A1 (en) * 2018-10-29 2020-05-07 Spin Therapeutics, Llc Compositions and methods for alpha-1-antitrypsin disorders
WO2020163264A1 (en) * 2019-02-04 2020-08-13 Neutrolis, Inc. Engineered human extracellular dnase enzymes for drug candidate selection
WO2020186111A2 (en) * 2019-03-12 2020-09-17 xCella Biosciences, Inc. Vista-binding antibodies and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PLOS ONE, vol. 7(9), e44482, JPN6025037401, 2012, ISSN: 0005804114 *
SCIENCE TRANSLATIONAL MEDICINE, vol. 11(498), JPN6025037402, 2019, ISSN: 0005804113 *

Also Published As

Publication number Publication date
KR20230124633A (ko) 2023-08-25
IL303712A (en) 2023-08-01
MX2023007326A (es) 2023-08-22
EP4262840A1 (en) 2023-10-25
CA3202397A1 (en) 2022-06-23
ZA202306571B (en) 2024-11-27
CN116887850A (zh) 2023-10-13
WO2022133326A1 (en) 2022-06-23
AU2021400761A1 (en) 2023-07-06
US20240101630A1 (en) 2024-03-28
EP4262840A4 (en) 2024-11-20
AU2021400761A9 (en) 2024-10-10

Similar Documents

Publication Publication Date Title
JP2024500870A (ja) 二官能性線状融合コラーゲン局在化免疫調節分子およびその方法
JP7611173B2 (ja) 組換えｆａｐ結合タンパク質及びそれらの使用
CA3044556C (en) Combination therapy comprising an inflammatory immunocytokine and a chimeric antigen receptor (car)-t cell
Han et al. IL-15: IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization
US20220298212A1 (en) Recombinant 4-1bb binding proteins and their use
US20230031597A1 (en) Biased il2 muteins methods and compositions
CN113286817A (zh) Dll3结合蛋白及使用方法
CN112739379A (zh) 包含OX40抗原结合位点的Fc结合片段
JP2022520978A (ja) オルソポックスウイルス主要組織適合性複合体（ｍｈｃ）クラスｉ様タンパク質（ｏｍｃｐ）と腫瘍特異的結合パートナーを用いた二重特異性融合タンパク質
JP2023554379A (ja) 組換えｃｄ３結合タンパク質及びそれらの使用
US20250144178A1 (en) Pharmaceutical composition for cancer treatment comprising fusion protein including il-12 and anti-fap antibody and anticancer agent
Dehghan et al. Specific Targeting of Zinc Transporter LIV-1 with Immunocytokine Containing Anti-LIV-1 VHH and Human IL-2 and Evaluation of its In vitro Antitumor Activity
BR112020013854B1 (pt) Proteínas bifuncionais que combinam bloqueio de ponto de verificação para a terapia alvejada
HK1262220B (en) Combination therapy comprising an inflammatory immunocytokine and a chimeric antigen receptor (car)-t cell
HK1262220A1 (en) Combination therapy comprising an inflammatory immunocytokine and a chimeric antigen receptor (car)-t cell

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241001

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250617

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260331